Fatty acid-binding protein E-FABP restricts tumor growth by promoting IFN-b responses in tumor-associated macrophages

Cancer Research

Volumn 74, Issue 11, 2014, Pages 2986-2998

  Zhang, Yuwen ^a   Sun, Yanwen ^a   Rao, Enyu ^a   Yan, Fei ^a   Li, Qiang ^a   Zhang, Ying ^a   Silverstein, Kevin A T ^a   Liu, Shujun ^a   Sauter, Edward ^b   Cleary, Margot P ^a   Li, Bing ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CXCL11 CHEMOKINE; EPIDERMAL FATTY ACID BINDING PROTEIN; FAT DROPLET; FATTY ACID BINDING PROTEIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; UNCLASSIFIED DRUG; LIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CD4 LYMPHOCYTE PERCENTAGE; CELL PROTECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; HUMAN; IMMUNOSURVEILLANCE; INTRACELLULAR SIGNALING; LIPID METABOLISM; LYMPHOCYTE ACTIVATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; UPREGULATION; ANIMAL; C57BL MOUSE; EPIDERMIS; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENE EXPRESSION; GENETICS; IMMUNOLOGY; MACROPHAGE; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE;

ANIMALS; EPIDERMIS; FATTY ACID-BINDING PROTEINS; FEMALE; GENE EXPRESSION; HUMANS; INTERFERON-BETA; KILLER CELLS, NATURAL; LIPIDS; MACROPHAGES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; TUMOR CELLS, CULTURED;

EID: 84902144284     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2689     Document Type: Article

References (48)

1. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008;7:489-503.
2. Hertzel AV, Bernlohr DA. The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function. Trends Endocrinol Metab 2000;11:175-80.
3. Furuhashi M, Tuncman G, Gorgun CZ, Makowski L, Atsumi G, Vaillancourt E, et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007;447:959-65.
4. Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KT, et al. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 2005;z: 107-19.
5. Milner KL, van der Poorten D, Xu A, Bugianesi E, Kench JG, Lam KS, et al. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology 2009;49: 1926-34.
6. Reynolds JM, Liu Q, Brittingham KC, Liu Y, Gruenthal M, Gorgun CZ, et al. Deficiency of fatty acid-binding proteins in mice confers protection from development of experimental autoimmune encephalomyelitis. J Immunol 2007;179:313-21.
7. Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: A 5-year prospective study. Circulation 2007;115:1537-43.
8. Li B, Reynolds JM, Stout RD, Bernlohr DA, Suttles J. Regulation of Th17 differentiation by epidermal fatty acid-binding protein. J Immunol 2009;182:7625-33.
9. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005;6:722-9.
10. Smyth MJ. Type I interferon and cancer immunoediting. Nat Immunol 2005;6:646-8.
11. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, et al. Host type I IFN signals are required for antitumor CD8 T cell responses through CD8{alpha} dendritic cells. J Exp Med 2011;208: 2005-16.
12. Fuertes MB, Woo SR, Burnett B, Fu YX, Gajewski TF. Type I interferon response and innate immune sensing of cancer. Trends Immunol 2013;34:67-73.
13. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-6.
14. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010;22:231-7.
15. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-8.
16. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008;8:958-69.
17. Ewens A, Mihich E, Ehrke MJ. Distant metastasis from subcutaneously grown E0771 medullary breast adenocarcinoma. Anticancer Res 2005;25:3905-15.
18. Mantovani A, Marchesi F, Porta C, Sica A, Allavena P. Inflammation and cancer: breast cancer as a prototype. Breast 2007;16 Suppl 2: S27-S33.
19. Beck AH, Espinosa I, Edris B, Li R, Montgomery K, Zhu S, et al. The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clin Cancer Res 2009;15:778-87.
20. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008;14:518-27.
21. Laoui D, Movahedi K, Van OE, Van den Bossche J, Schouppe E, Mommer C, et al. Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. Int J Dev Biol 2011;55:861-7.
22. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605-12.
23. Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 2010;70:5728-39.
24. Hallam S, Escorcio-Correia M, Soper R, Schultheiss A, Hagemann T. Activated macrophages in the tumour microenvironment-dancing to the tune of TLR and NF-KAPPAB. J Pathol 2009;219:143-52.
25. Murray RZ, Wylie FG, Khromykh T, Hume DA, Stow JL. Syntaxin 6 and Vti1b form a novel SNARE complex, which is up-regulated in activatedmacrophages to facilitate exocytosis of tumor necrosis Factor-alpha. J Biol Chem 2005;280:10478-83.
26. Jiang X, Chen ZJ. Viperin links lipid bodies to immune defense. Immunity 2011;34:285-7.
27. Saitoh T, Satoh T, Yamamoto N, Uematsu S, Takeuchi O, Kawai T, et al. Antiviral protein Viperin promotes Toll-like receptor 7- And Toll-like receptor 9-mediated type I interferon production in plasmacytoid dendritic cells. Immunity 2011;34:352-63.
28. Namatame I, Tomoda H, Arai H, Inoue K, Omura S. Complete inhibition of mouse macrophage-derived foam cell formation by triacsin C. J Biochem 1999;125:319-27.
29. Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, Cohen P, et al. Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res 2006;12:4662-70.
30. Kurachi M, Kurachi J, Suenaga F, Tsukui T, Abe J, Ueha S, et al. Chemokine receptor CXCR3 facilitates CD8() T cell differentiation into short-lived effector cells leading to memory degeneration. J Exp Med 2011;208:1605-20.
31. Wendel M, Galani IE, Suri-Payer E, Cerwenka A. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res 2008;68:8437-45.
32. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006;6:836-48.
33. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007;117:1137-46.
34. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005;115:1111-9.
35. Kannan-Thulasiraman P, Seachrist DD, Mahabeleshwar GH, Jain MK, Noy N. Fatty acid-binding protein 5 and PPAR beta/delta are critical mediators of epidermal growth factor receptor-induced carcinoma cell growth. J Biol Chem 2010;285:19106-15.
36. Levi L, Lobo G, Doud MK, von LJ, Seachrist D, Tochtrop GP, et al. Genetic ablation of the fatty acid binding protein FABP5 suppresses HER2-induced mammary tumorigenesis. Cancer Res 2013;73:4770-80.
37. Liu RZ, Graham K, Glubrecht DD, Germain DR, Mackey JR, Godbout R. Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy. Am J Pathol 2011;178:997-1008.
38. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011;208: 1989-2003.
39. Fonseca C, Dranoff G. Capitalizing on the immunogenicity of dying tumor cells. Clin Cancer Res 2008;14:1603-8.
40. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, et al. Immunogenic cancer cell death: A key-lock paradigm. Curr Opin Immunol 2008;20:504-11.
41. Wang Z, Choi MK, Ban T, Yanai H, Negishi H, Lu Y, et al. Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing molecules. Proc Natl Acad Sci U S A 2008;105: 5477-82.
42. Walther TC, Farese RV Jr. Lipid droplets and cellular lipid metabolism. Annu Rev Biochem 2012;81:687-714.
43. Hinson ER, Cresswell P. The N-terminal amphipathic alpha-helix of viperin mediates localization to the cytosolic face of the endoplasmic reticulum and inhibits protein secretion. J Biol Chem 2009;284: 4705-12.
44. Hinson ER, Cresswell P. The antiviral protein, viperin, localizes to lipid droplets via its N-terminal amphipathic alpha-helix. Proc Natl Acad Sci U S A 2009;106:20452-7.
45. Farese RV Jr, Walther TC. Lipid droplets finally get a little R-E-S-P-E-CT. Cell 2009;139:855-60.
46. Swann JB, HayakawaY, Zerafa N, Sheehan KC, Scott B, Schreiber RD, et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol 2007;178:7540-9.
47. Trinchieri G. Type I interferon: friend or foe? J Exp Med 2010;207: 2053-63.
48. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51.